Publication:
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ)

Simple item page
dc.contributor.authorsMalmstrom, A.; Gronberg, B. H.; Stupp, R.; Marosi, C.; Frappaz, D.; Schultz, H. P.; Abacioglu, M. U.; Kinhult, S.; Henriksson, R.
dc.date.accessioned2022-03-10T17:50:19Z
dc.date.accessioned2026-01-11T13:33:51Z
dc.date.available2022-03-10T17:50:19Z
dc.date.issued2010
dc.identifier.doi10.1200/jco.2010.28.18_suppl.lba2002
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/221317
dc.identifier.wosWOS:000208880800018
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleGlioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ)
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.issue18
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume28

Files

Collections

Araştırma Çıktıları